Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study is in two stages:
Stage 1 purpose is to assess safety, tolerability, and efficacy of multiple TAB08 doses in
patients with active Rheumatoid Arthritis in which methotrexate (MTX) treatment is not enough
effective.
Stage 2 purpose is to assess efficacy parameters (ACR criteria) of at least one selected
TAB08 dose in extended patient population with active Rheumatoid Arthritis in which
methotrexate (MTX) treatment with at least 10 mg/week is not enough effective.